• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2 型糖尿病中的脂肪变性和 NASH。

Steatosis and NASH in type 2 diabetes.

机构信息

INSERM UMRS 1138, Sorbonne Université, Centre de Recherche des Cordeliers, 75006, Paris, France; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006, Paris, France.

INSERM UMRS 1138, Sorbonne Université, Centre de Recherche des Cordeliers, 75006, Paris, France; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006, Paris, France; Assistance Publique-Hôpitaux de Paris, Department of Endocrinology, Nutrition, and Diabetes, Paris, France; Institute of Cardiometabolism and Nutrition, ICAN, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière hospital, Paris, France.

出版信息

Biochimie. 2017 Dec;143:37-41. doi: 10.1016/j.biochi.2017.10.019. Epub 2017 Oct 31.

DOI:10.1016/j.biochi.2017.10.019
PMID:29097281
Abstract

Non Alcoholic Fatty Liver Disease (NAFLD) is currently the most common chronic liver disease in the world, encompassing various conditions ranging from simple steatosis, steatohepatitis, to fibrosis and cirrhosis. The association between NAFLD and Type 2 Diabetes (T2D) is strong and complex, given that the prevalence of NAFLD is particularly high in individuals with Type 2 Diabetes. In fact, insulin resistance occurring in this metabolic disease can promote NAFLD development, and vice versa, NAFLD can enhance insulin resistance. In this review, we focus on the mechanisms linking NAFLD and T2D, including fatty acid accumulation, inflammation, oxidative stress etc. We also discuss about situations showing a dissociation between steatosis and insulin resistance, in order to provide new insights for NAFLD therapeutic targets.

摘要

非酒精性脂肪性肝病(NAFLD)是目前世界上最常见的慢性肝病,涵盖了从单纯性脂肪变性、脂肪性肝炎到纤维化和肝硬化等各种疾病。NAFLD 与 2 型糖尿病(T2D)之间存在着密切而复杂的关联,因为 2 型糖尿病患者中 NAFLD 的患病率特别高。事实上,这种代谢性疾病中发生的胰岛素抵抗可以促进 NAFLD 的发展,反之亦然,NAFLD 也可以增强胰岛素抵抗。在这篇综述中,我们重点讨论了将 NAFLD 和 T2D 联系起来的机制,包括脂肪酸积累、炎症、氧化应激等。我们还讨论了在脂肪变性和胰岛素抵抗之间出现脱偶联的情况,以期为 NAFLD 的治疗靶点提供新的见解。

相似文献

1
Steatosis and NASH in type 2 diabetes.2 型糖尿病中的脂肪变性和 NASH。
Biochimie. 2017 Dec;143:37-41. doi: 10.1016/j.biochi.2017.10.019. Epub 2017 Oct 31.
2
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.2型糖尿病合并非酒精性脂肪性肝病患者的治疗:当前方法与未来方向
Diabetologia. 2016 Jun;59(6):1112-20. doi: 10.1007/s00125-016-3952-1. Epub 2016 Apr 21.
3
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?代谢综合征与非酒精性脂肪性肝病:胰岛素抵抗是其中的关联因素吗?
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:55-65. doi: 10.1016/j.mce.2015.02.018. Epub 2015 Feb 24.
4
Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.激活转录因子 3 是连接肝脂肪变性与葡萄糖稳态受损的靶分子。
J Hepatol. 2017 Aug;67(2):349-359. doi: 10.1016/j.jhep.2017.03.023. Epub 2017 Mar 30.
5
[Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].非酒精性脂肪性肝炎发病机制分析与防治
Nihon Eiseigaku Zasshi. 2015;70(3):197-204. doi: 10.1265/jjh.70.197.
6
Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.针对代谢、胰岛素抵抗和糖尿病治疗非酒精性脂肪性肝炎。
Diabetes. 2018 Dec;67(12):2485-2493. doi: 10.2337/dbi18-0024.
7
Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.非酒精性脂肪性肝病和丙型肝炎病毒感染中的2型糖尿病——肝脏:成为焦点的“火枪手”
Int J Mol Sci. 2016 Mar 9;17(3):355. doi: 10.3390/ijms17030355.
8
Non-alcoholic fatty liver disease and dyslipidemia: An update.非酒精性脂肪性肝病与血脂异常:最新进展
Metabolism. 2016 Aug;65(8):1109-23. doi: 10.1016/j.metabol.2016.05.003. Epub 2016 May 13.
9
Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.2 型糖尿病中非酒精性脂肪性肝病的药物治疗管理。
Expert Rev Clin Pharmacol. 2017 May;10(5):535-547. doi: 10.1080/17512433.2017.1300059. Epub 2017 Mar 6.
10
Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.异位脂肪、胰岛素抵抗与非酒精性脂肪性肝病。
Proc Nutr Soc. 2013 Nov;72(4):412-9. doi: 10.1017/S0029665113001249. Epub 2013 May 14.

引用本文的文献

1
Disrupted metabolic flux balance between pyruvate dehydrogenase and pyruvate carboxylase in human fatty liver.人类脂肪肝中丙酮酸脱氢酶和丙酮酸羧化酶之间代谢通量平衡的破坏。
Metabolism. 2025 Apr;165:156151. doi: 10.1016/j.metabol.2025.156151. Epub 2025 Jan 29.
2
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action.认识非酒精性脂肪性肝病的负担:行动时刻到了。
Diabetes Spectr. 2024 Winter;37(1):9-19. doi: 10.2337/dsi23-0010. Epub 2024 Feb 15.
3
Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice.
代谢相关脂肪性肝病饮食与运动的非药物治疗方法:弥合研究与临床实践之间的差距
J Pers Med. 2024 Jan 1;14(1):61. doi: 10.3390/jpm14010061.
4
Global Trends of Treatment for NAFLD from 2012 to 2021: A Bibliometric and Mapping Analysis.全球 2012-2021 年非酒精性脂肪性肝病治疗趋势:文献计量学和图谱分析。
Endocr Metab Immune Disord Drug Targets. 2024;24(5):573-584. doi: 10.2174/0118715303230418230925060312.
5
Food Polyphenols and Type II Diabetes Mellitus: Pharmacology and Mechanisms.食物多酚与 II 型糖尿病:药理学与机制
Molecules. 2023 May 10;28(10):3996. doi: 10.3390/molecules28103996.
6
A retrospective study to find out the correlation between NAFLD, diabetes, and obesity in Indian patients.一项旨在找出印度患者非酒精性脂肪性肝病(NAFLD)、糖尿病和肥胖症之间相关性的回顾性研究。
J Family Med Prim Care. 2022 Jul;11(7):3504-3510. doi: 10.4103/jfmpc.jfmpc_2212_21. Epub 2022 Jul 22.
7
Assessment of Predictive Factors of Hepatic Steatosis Diagnosed by Vibration Controlled Transient Elastography (VCTE) in Chronic Hepatitis C Virus-Infected Patients.慢性丙型肝炎病毒感染患者中通过振动控制瞬时弹性成像(VCTE)诊断肝脂肪变性的预测因素评估
J Community Hosp Intern Med Perspect. 2022 Jul 4;12(4):58-65. doi: 10.55729/2000-9666.1071. eCollection 2022.
8
Genetic and Pharmacological Inhibition of GCN2 Ameliorates Hyperglycemia and Insulin Resistance in Type 2 Diabetic Mice.GCN2的基因和药理学抑制改善2型糖尿病小鼠的高血糖和胰岛素抵抗。
Antioxidants (Basel). 2022 Aug 16;11(8):1584. doi: 10.3390/antiox11081584.
9
Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.用于2型糖尿病合并非酒精性脂肪性肝病的中草药:一项系统评价和荟萃分析。
Front Pharmacol. 2022 Jun 27;13:863839. doi: 10.3389/fphar.2022.863839. eCollection 2022.
10
[TSPAN8 is involved in lipid metabolism in non-alcoholic fatty liver disease in mice].TSPAN8参与小鼠非酒精性脂肪性肝病的脂质代谢
Nan Fang Yi Ke Da Xue Xue Bao. 2022 May 20;42(5):705-711. doi: 10.12122/j.issn.1673-4254.2022.05.11.